SHANGHAI – Biotech entrepreneurs in China pursuing innovative drugs often straddle two, if not three, worlds. They have a deep knowledge of the scientific, regulatory and commercial landscape of China as well as the U.S. And, crucially, they have the ability to envision what the China market of the future will look like.
SHANGHAI – When investors started pouring capital into Chinese biotechs like Hua Medicine Ltd., Innovent Biologics Inc. or Cstone Pharmaceuticals Co. Ltd., it was reasonable to wonder what exits they were planning. For a long time, China's major stock exchanges only allowed revenue-generating firms to list, making Nasdaq often the best bet, if not an ideal solution for Chinese biotechs.
SHANGHAI – When investors started pouring capital into Chinese biotechs like Hua Medicine Ltd., Innovent Biologics Inc. or Cstone Pharmaceuticals Co. Ltd., it was reasonable to wonder what exits they were planning. For a long time, China's major stock exchanges only allowed revenue-generating firms to list, making Nasdaq often the best bet, if not an ideal solution for Chinese biotechs.
SHANGHAI – Biotech entrepreneurs in China pursuing innovative drugs often straddle two, if not three, worlds. They have a deep knowledge of the scientific, regulatory and commercial landscape of China as well as the U.S. And, crucially, they have the ability to envision what the China market of the future will look like.
SHANGHAI – At this year's China Healthcare Investment Conference, the most insistent voices were not Chinese but American. Three speakers – a former U.S. federal judge, a leading biotech entrepreneur and a China pharma executive – each made their case for China's biopharma industry to have more influence, not just in China but globally.
SHANGHAI – At this year's China Healthcare Investment Conference, the most insistent voices were not Chinese but American. Three speakers – a former U.S. federal judge, a leading biotech entrepreneur and a China pharma executive – each made their case for China's biopharma industry to have more influence, not just in China but globally.
SHANGHAI – The first Wuxi Healthcare Forum held in China was a notably upbeat and optimistic affair. Several panel moderators encouraged blue sky thinking by asking a variant on the same question: What technologies and advances are the most exciting or have the greatest potential to disrupt the industry in the next five to 10 years? Speakers from China, the U.K., Europe, the U.S. and Canada gamely shared their prognostications for the future.
SHANGHAI – By most measures, the inaugural Wuxi Healthcare Forum last week was a success. The free event was attended by more than 2,000 mostly Chinese participants, many of whom stood in the aisles of the swanky St. Regis Shanghai Jingan ballroom to hear about China's role in the future of health care.
SHANGHAI – The first Wuxi Healthcare Forum held in China was a notably upbeat and optimistic affair. Several panel moderators encouraged blue sky thinking by asking a variant on the same question: What technologies and advances are the most exciting or have the greatest potential to disrupt the industry in the next five to 10 years? Speakers from China, the U.K., Europe, the U.S. and Canada gamely shared their prognostications for the future.
SHANGHAI – By most measures, the inaugural Wuxi Healthcare Forum last week was a success. The free event was attended by more than 2,000 mostly Chinese participants, many of whom stood in the aisles of the swanky St. Regis Shanghai Jingan ballroom to hear about China's role in the future of health care.
